Rabies human monoclonal antibodies belong to immune globulins.

Rabies human monoclonal antibodies (RMAbs) primarily provide immediate passive immunity to individuals exposed to the rabies virus, particularly in high-risk situations. 

Rabies human monoclonal antibodies are primarily administered intramuscularly, typically at the site of the potential rabies exposure. The best route of administration depends on the individual's needs and preferences, but oral administration is typically the most convenient.

Common side effects of Rabies human monoclonal antibodies may include localized reactions at the injection site, such as pain, swelling, redness, and a low-grade fever. Serious side effects are rare but may involve severe allergic reactions (anaphylaxis) that can result in symptoms like difficulty breathing, facial or throat swelling, hives, and a drop in blood pressure.

Rabies human monoclonal antibodies may risk severe allergic reactions, including anaphylaxis, which can be life-threatening. Some individuals may experience a mild increase in body temperature (low-grade fever) as a common side effect.

Assess the patient's history of allergies, particularly any components of Rabies human monoclonal antibodies or previous reactions to monoclonal antibody therapies. Administer it promptly after potential rabies exposure, as delay can reduce their effectiveness.

Check if the person is allergic to any Rabies human monoclonal antibodies components or has previously had problems with similar treatments. Give it soon after a potential rabies exposure because delays can make them less effective. Look at the person's health condition, especially if they have a weak immune system, as it might not work well in such cases. Consider carefully using it during pregnancy or breastfeeding to weigh potential risks and benefits. Keep a close eye on the person during and after the treatment, especially if they have other health problems. Understand if the person has received rabies vaccines before because it is often given with these vaccines. If someone faces multiple possible rabies sources, consider giving more of its doses. If the person is very young or old, consider their age and weight to decide how much to use. 

1. Sudarshan MK. World Health Organization 2018 Guidelines on Rabies Prophylaxis: Contentious Issues. Pediatr Inf Dis 2019;1(4):154–156, https://www.pidjournal.com/doi/PID/pdf/10.5005/jp-journals-10081-1226
2. Thomas Moulenat et al., Purified Vero Cell Rabies Vaccine (PVRV, Verorab®): A Systematic Review of Intradermal Use Between 1985 and 2019, Trop. Med. Infect. Dis., 2020, 5, 40, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157209/pdf/tropicalmed-05-00040.pdf
3. Serum Institute of India Pvt Ltd, [Revised on 2021] [Accessed on 10th Oct 2023], https://www.seruminstitute.com/product_ind_rabishield.php
4. Anwith, H S & Ravish, Haradanahalli & Ashwathnarayana, Doddabele, Safety of new indigenous human Rabies Monoclonal Antibody (RMAb) for Post Exposure Prophylaxis, Indian Journal of Community Health, 2018, 30, 196-201, https://www.researchgate.net/publication/328743661_Safety_of_new_indigenous_human_Rabies_Monoclonal_Antibody_RMAb_for_Post_Exposure_Prophylaxis_Corresponding_Author_Citation_Article_Cycle

The drug information on this page is not a substitute for medical advice; it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.